These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 35662526)

  • 1. Glucagon-like peptide-1 receptor agonists as anti-inflammatory agents: A potential mode of cardiovascular benefits.
    Salem AM; Bain SC; Obaid DR
    Atherosclerosis; 2022 Jul; 352():83-84. PubMed ID: 35662526
    [No Abstract]   [Full Text] [Related]  

  • 2. [Heart and diabetes : What is the importance of GLP-1 receptor agonists in cardiology?].
    Moellmann J; Lehrke M
    Herz; 2022 Oct; 47(5):434-441. PubMed ID: 35857081
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glucagon-Like Peptide-1 Receptor Agonists and Cardiovascular Risk Reduction in Type 2 Diabetes Mellitus: Is It a Class Effect?
    Li Y; Rosenblit PD
    Curr Cardiol Rep; 2018 Sep; 20(11):113. PubMed ID: 30259238
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glucagon-like Peptide-1 Receptor Agonists and Cardiovascular Events: Class Effects versus Individual Patterns.
    Lim S; Kim KM; Nauck MA
    Trends Endocrinol Metab; 2018 Apr; 29(4):238-248. PubMed ID: 29463450
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glucagon like peptide-1 and its receptor agonists: Their roles in management of Type 2 diabetes mellitus.
    Gupta A; Jelinek HF; Al-Aubaidy H
    Diabetes Metab Syndr; 2017; 11(3):225-230. PubMed ID: 27884496
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Research Progress on the Cardiovascular Protective Effect of Glucagon-Like Peptide-1 Receptor Agonists.
    Song R; Qian H; Wang Y; Li Q; Li D; Chen J; Yang J; Zhong J; Yang H; Min X; Xu H; Yang Y; Chen J
    J Diabetes Res; 2022; 2022():4554996. PubMed ID: 35434139
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glucagon-like peptide-1 (GLP-1) receptor agonists and their cardiovascular benefits-The role of the GLP-1 receptor.
    Helmstädter J; Keppeler K; Küster L; Münzel T; Daiber A; Steven S
    Br J Pharmacol; 2022 Feb; 179(4):659-676. PubMed ID: 33764504
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Consensus recommendations on utilizing glucagon-like peptide-1(GLP-1) receptor agonists in the treatment of type 2 diabetes mellitus].
    ;
    Zhonghua Nei Ke Za Zhi; 2020 Nov; 59(11):836-846. PubMed ID: 33120487
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glucagon-Like Peptide-1 Receptor Agonists in Adult Patients With Type 2 Diabetes: Review of Cardiovascular Outcome Trials.
    Varin EM; McLean BA; Lovshin JA
    Can J Diabetes; 2020 Feb; 44(1):68-77. PubMed ID: 31699625
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in Cardiac Disorders.
    Wroge J; Williams NT
    Ann Pharmacother; 2016 Dec; 50(12):1041-1050. PubMed ID: 27531946
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors for cardiovascular and renal protection: A treatment approach far beyond their glucose-lowering effect.
    Gómez-Huelgas R; Sanz-Cánovas J; Cobos-Palacios L; López-Sampalo A; Pérez-Belmonte LM
    Eur J Intern Med; 2022 Feb; 96():26-33. PubMed ID: 34799233
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Editorial: Do Some Glucagon-Like-Peptide-1 Receptor Agonists (GLP-1 RA) Reduce Macrovascular Complications of Type 2 Diabetes Mellitus A Commentary on the Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER) Trial.
    Athyros VG; Katsiki N; Tentolouris N
    Curr Vasc Pharmacol; 2016; 14(5):469-473. PubMed ID: 27633290
    [No Abstract]   [Full Text] [Related]  

  • 13. Cardiovascular safety and benefits of GLP-1 receptor agonists.
    Dalsgaard NB; Brønden A; Vilsbøll T; Knop FK
    Expert Opin Drug Saf; 2017 Mar; 16(3):351-363. PubMed ID: 28102093
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiovascular effectiveness of glucagon-like peptide 1 receptor agonists versus dipeptidyl peptidase-4 inhibitors in type 2 diabetes: A meta-analysis based on propensity score-matched studies.
    Xu L; Zheng XQ; Liao XX
    Prim Care Diabetes; 2022 Feb; 16(1):207-210. PubMed ID: 34953749
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Endogenous glucagon-like peptide (GLP)-1 as alternative for GLP-1 receptor agonists: Could this work and how?
    Smits MM; Holst JJ
    Diabetes Metab Res Rev; 2023 Nov; 39(8):e3699. PubMed ID: 37485788
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Updated Meta-Analysis of Cardiovascular Outcome Trials Evaluating Cardiovascular Efficacy of Glucagon-Like Peptide-1 Receptor Agonists.
    Patoulias D; Papadopoulos C; Kassimis G; Karagiannis A; Doumas M
    Am J Cardiol; 2021 Nov; 159():143-146. PubMed ID: 34497008
    [No Abstract]   [Full Text] [Related]  

  • 17. Cardiovascular benefits of SGLT2 inhibitors and GLP-1 receptor agonists in Type 2 diabetes.
    Med Lett Drugs Ther; 2019 Feb; 61(1566):26-28. PubMed ID: 30845101
    [No Abstract]   [Full Text] [Related]  

  • 18. Sex Differences in Cardiovascular Effectiveness of Newer Glucose-Lowering Drugs Added to Metformin in Type 2 Diabetes Mellitus.
    Raparelli V; Elharram M; Moura CS; Abrahamowicz M; Bernatsky S; Behlouli H; Pilote L
    J Am Heart Assoc; 2020 Jan; 9(1):e012940. PubMed ID: 31902326
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inquiries Into the Mechanisms by Which GLP-1 Receptor Agonists Reduce Cardiovascular Risk in Diabetes.
    Inzucchi SE; Arai AE
    J Am Coll Cardiol; 2024 Aug; 84(6):558-560. PubMed ID: 39084830
    [No Abstract]   [Full Text] [Related]  

  • 20. Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors.
    Nauck MA; Meier JJ; Cavender MA; Abd El Aziz M; Drucker DJ
    Circulation; 2017 Aug; 136(9):849-870. PubMed ID: 28847797
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.